Nona Biosciences, a US-based global biotechnology company, announced on Friday that BeiGene Ltd, a US-based global, science-driven oncology company, has exercised its exclusive option to acquire global development, manufacturing and commercialisation rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona Biosciences.
This ADC was manufactured under the partnership contract set up between Nona Biosciences and DualityBio in 2022.
Under the terms of the agreement, Nona Biosciences granted DualityBio exclusive rights to certain monoclonal antibodies targeting specific tumours, enabling the development of first-in-class ADC candidates worldwide.
Atossa Therapeutics secures new US patent for (Z)-endoxifen formulations
Akeso's Ebdarokimab approved in China for moderate-to-severe plaque psoriasis
Ymmunobio's YB-800 ADCs achieve proof of concept in preclinical in vitro and in vivo Tests
SparX to present Phase 1 clinical update during AACR 2025
Hoth Therapeutics secures Japanese patent for RNA-based therapy targeting KIT gene
Hoth Therapeutics reports positive initial data from Phase 2a pruritus trial
Galmed reveals novel pharmacodynamic blood markers for Aramchol SCD1 inhibitor
Telix Pharmaceuticals' TLX101 glioma therapy candidate shows promising efficacy
FluoGuide begins phase II trial of FG001 for head and neck cancer
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
Sumitomo Pharma America signs research and development agreement with NCI
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Scancell partners with NHS Cancer Vaccine Launch Pad to accelerate melanoma trial recruitment